Where to buy 2-FMA for sale online

When it comes to purchasing research chemicals such as 2-FMA online, selecting a reliable seller is of paramount importance. The world of designer drugs and research chemicals can be murky, with many vendors claiming to offer the best products for sale. However, caution is advised as not all vendors are trustworthy or provide high-quality substances.
One crucial factor to consider when choosing a research chemical seller is reputation. Reputable vendors have a history of providing legitimate, pure, and accurately labelled chemicals to researchers. It’s essential to do thorough research and read customer reviews to gauge the credibility of a seller. Many online communities and forums dedicated to researching chemicals can offer valuable insights into the experiences of other buyers.
Another critical aspect is transparency. Trustworthy sellers provide detailed information about their products, including chemical composition, purity levels, and any potential risks associated with their use. They prioritize their customers’ safety and well-being and scientific research’s integrity.
Additionally, the legality of the research chemical should be considered. Regulations regarding the sale and purchase of research chemicals vary by country and region. A reputable seller will adhere to these regulations and guide customers to ensure compliance.
While the convenience of buying research chemicals online is undeniable, exercising caution and due diligence is essential. Avoid sellers making exaggerated claims or offering prices that seem too good to be true, as this may indicate substandard or impure products. Furthermore, beware of vendors with a lack of transparency or those who prioritize profits over the safety and integrity of research.


2-Fluoromethamphetamine, commonly called 2-FMA, belongs to the amphetamine class and acts as a novel stimulant. This compound is similar to methamphetamine and is closely related to substances like 2-FA, 3-FA, and 4-FMA. The stimulant effects of 2-FMA are primarily mediated by its interaction with dopamine and norepinephrine receptors in the brain.
The presence of 2-FMA in the online research chemical market was first documented in August 2007. It emerged alongside other fluorinated amphetamines like 2-FA and 4-FA. Notably, 2-FMA remains relatively obscure within clinical and research literature, with limited available data.
Subjective effects associated with 2-FMA encompass stimulation, heightened focus, increased motivation, enhanced libido, appetite suppression, and euphoria. This substance is typically consumed orally or through insufflation, as attempting to vaporize it can release toxic compounds due to the breakdown of carbon-fluoride bonds. Users often compare 2-FMA and lisdexamfetamine (Vyvanse) in terms of duration, potency, and effectiveness as a study or productivity aid. However, it’s crucial to note that dosages exceeding the heavy range may lead to heightened adverse effects, including elevated blood pressure and increased heart rate.
Unfortunately, comprehensive data concerning the pharmacological properties, metabolism, and toxicity of 2-FMA is scarce. Consequently, it is strongly recommended that individuals exercise caution and adhere to harm-reduction practices when using this substance. Given the limited understanding of its effects and potential risks, responsible usage is paramount to ensure the safety and well-being of those exploring its properties.

show IUPAC name
CAS Number1017176-48-5 
PubChem CID24257263
CompTox Dashboard (EPA)DTXSID90640530 
Chemical and physical data
Molar mass167.227 g·mol−1


2-Fluoromethamphetamine, often called 2-FMA, is a synthetic compound in the substituted amphetamine class. These amphetamine class molecules are characterized by a phenethylamine core structure featuring a phenyl ring linked to an amino (NH2) group through an ethyl chain, with an additional methyl substitution at the Rα position. In simpler terms, amphetamines can be described as alpha-methylated phenethylamines. 2-FMA shares a common structural feature with methamphetamine, as it contains a methyl group attached to the endmost amine RN of the amphetamine core. This structural alteration is also shared with methamphetamine, making 2-FMA the 2-position fluorinated analogue of methamphetamine and the N-methylated counterpart of 2-FA (2-fluoroamphetamine).


While 2-FMA has not undergone extensive formal research comparable to traditional amphetamines, it is theorized to function as a dual-acting agent, releasing dopamine and norepinephrine. In essence, it operates by enhancing the levels of these neurotransmitters in the brain. This mechanism involves binding to and partially obstructing the transporter proteins responsible for clearing dopamine and norepinephrine from the synaptic cleft. Consequently, this inhibition permits the accumulation of dopamine and norepinephrine within the brain, ultimately leading to the onset of stimulating and euphoric effects.

Subjective effects

  1. Stimulation: 2-FMA is recognized for its robust and energetic stimulation, falling somewhere between the potency of methamphetamine and milder substances like modafinil, caffeine, or methylphenidate. This stimulation is often described as “clean” but can lead to physical restlessness, jaw clenching, bodily shakes, and vibrations, particularly at higher doses.
  2. Physical Euphoria: While more pronounced at higher doses, 2-FMA can induce physical euphoria. However, it is typically milder than other stimulants such as amphetamine, lisdexamfetamine, or methylphenidate.
  3. Tactile Enhancement: Users may experience heightened tactile sensitivity.
  4. Stamina Enhancement: 2-FMA can enhance endurance and physical stamina.
  5. Cardiovascular Effects: Some users report abnormal heartbeats, increased heart rate, and elevated blood pressure, especially at higher doses.
  6. Appetite Suppression: 2-FMA is known to suppress appetite.
  7. Bronchodilation: This effect facilitates easier breathing.
  8. Dehydration and Dry Mouth: Users may experience dry mouth, increased perspiration, and frequent urination.
  9. Pupil Dilation: Pupil dilation is more prominent at higher doses and during the comedown.
  10. Teeth Grinding: Similar to MDMA, teeth grinding may occur, although generally less intense.
  11. Temporary Erectile Dysfunction: Some users may experience difficulty achieving or maintaining an erection.
  12. Vasoconstriction: Blood vessels may constrict, potentially causing discomfort.
  13. Restless Legs: A sensation of restless legs can be present.
  14. Visual Distortions: Visual effects are typically subtle, with mild distortions and brightness alterations. Hallucinatory states and transformations are rare and usually occur with high doses or sleep deprivation.
  15. Cognitive Enhancement: Users report improved analysis, focus, motivation, and bodily control. Mental euphoria and heightened libido can also manifest.
  16. Anxiety and Paranoia: These effects may occur at high doses or with prolonged use.
  17. Compulsive Redosing: Some users may feel compelled to reduce.
  18. Delusion, Disinhibition, and Ego Inflation: These effects are possible, particularly at higher doses.
  19. Emotion Suppression: Users may experience emotional numbness.
  20. Time Distortion: Time can appear to pass quickly.
  21. After Effects (Comedown): After the peak, users may encounter a “comedown” characterized by negative feelings, cognitive fatigue, depersonalization, depression, irritability, and motivation suppression. Psychosis, thought deceleration and memory suppression have also been reported.

It’s crucial to exercise caution when using 2-FMA, as its effects can vary widely, and adverse reactions may occur, especially at higher doses. Users should be mindful of potential risks and prioritize harm-reduction practices.


Toxicity and Health Effects:

The scientific study of the toxicity and long-term health consequences of recreational 2-FMA use needs to be more present, primarily due to its limited history of human consumption. Anecdotal reports from users experimenting with 2-FMA at low to moderate doses suggest no significant adverse health effects. However, it’s essential to approach this substance cautiously, as the exact toxic dosage remains unknown. Harm reduction practices are highly recommended.

Dependence and Abuse Potential:

Like other stimulants, chronic use of 2-FMA carries a moderate risk of addiction and a high potential for abuse. Psychological dependence can develop, leading to cravings and withdrawal symptoms upon cessation. Tolerance to its effects tends to build with prolonged and repeated use, necessitating larger doses for the same impact. It takes about 3 to 7 days for patience to reduce by half and 1 to 2 weeks to return to baseline without further consumption. Cross-tolerance exists with all dopaminergic stimulants, diminishing the effects of other stimulants after 2-FMA use.


Prolonged and high-dosage use of amphetamine-like compounds, including 2-FMA, can potentially result in stimulant psychosis characterized by symptoms like paranoia, hallucinations, and delusions. Approximately 5–15% of users may not fully recover from this condition. Antipsychotic medications may be effective in resolving acute amphetamine-induced psychosis.

Dangerous Interactions:

Combining 2-FMA with other substances can be perilous. Here are some known risky interactions:

  • Alcohol: The combination reduces the sedative effects of alcohol, potentially leading to excessive drinking, liver damage, and dehydration.
  • GHB/GBL: Stimulants increase respiration, allowing for higher sedative doses. However, if the stimulant wears off first, it may lead to respiratory arrest.
  • Opioids: Similar to GHB/GBL, opioids’ depressant effects can become overwhelming if the stimulant’s effects diminish first.
  • Cocaine: The mix can result in cardiac issues due to the combined cardiac effects of both substances.
  • Cannabis: Stimulants may increase anxiety, thought loops, and paranoia during cannabis use.
  • Caffeine: This combination can strain the heart and induce anxiety and physical discomfort.
  • Tramadol: Both substances raise the risk of seizures.
  • DXM: Both substances increase heart rate and can cause panic attacks, potentially leading to more severe heart issues.
  • Ketamine: Combining amphetamine and ketamine may result in psychoses resembling schizophrenia. This is due to complex pharmacological interactions between the two substances.
  • PCP and Methoxetamine: These combinations increase the risk of tachycardia, hypertension, and manic states.
  • Psychedelics (e.g., LSD, psilocybin): Combining stimulants with psychedelics may increase anxiety, paranoia, and thought loops.
  • 25x-NBOMe: The combination can result in tachycardia, hypertension, and, in extreme cases, heart failure.
  • 2C-T-x and 5-MeO-xxT: These substances have mild MAOI properties and may increase the risk of hypertensive crisis when combined with amphetamines.
  • DOx, aMT, MAOIs: These substances can interact unpredictably and increase the potency and duration of phenethylamines like 2-FMA.

Researching thoroughly and exercising caution when combining substances is essential, as dangerous interactions can have severe consequences, including life-threatening outcomes.

Legal status

Legal Status of 2-FMA:

The lawful Status of 2-FMA varies globally, often placing it in a legal grey area where its regulation is not explicitly defined as illegal or “scheduled.” However, it’s crucial to note that individuals may still face legal repercussions for their possession, especially under specific circumstances such as analogue laws or when possessing it intending to sell or consume.

  • Canada: In Canada, 2-FMA would be classified as Schedule I due to its Status as an analogue of Amphetamine.
  • China: Since October 2015, China has classified 2-FMA as a controlled substance.
  • Germany: Germany controls 2-FMA under Anlage I BtMG (Narcotics Act, Schedule I) since December 13, 2014. This means it is illegal to manufacture, possess, import, export, buy, sell, procure, or dispense without a license.
  • New Zealand: 2-FMA falls under the category of amphetamine analogues, making it a Schedule 3 controlled substance in New Zealand.
  • Switzerland: Switzerland designates 2-FMA as a controlled substance, named explicitly under Verzeichnis E.
  • Turkey: In Turkey, 2-FMA is classified as a drug and is illegal to possess, produce, supply, or import.
  • United Kingdom: 2-FMA is considered a Class A drug in the United Kingdom, a status attributed to it due to the amphetamine analogue clause within the Misuse of Drugs Act 1971.
  • Ukraine: 2-FMA is regarded as a narcotic substance and is strictly illegal.

The legal Status of 2-FMA can vary widely from one country to another, and individuals are encouraged to research and adhere to their specific national laws and regulations concerning this compound.


1. What is 2-FMA?

2-Fluoromethamphetamine (2-FMA) is a synthetic compound in the substituted amphetamine class. It shares similarities with amphetamines and is a structural analogue of methamphetamine.

2. What are the effects of 2-FMA?

Users report various effects, including stimulation, increased focus, motivation enhancement, elevated libido, appetite suppression, and euphoria. It is often compared to drugs like amphetamine and lisdexamfetamine (Vyvanse) for its productivity-enhancing properties.

3. Is 2-FMA safe to use?

The safety of 2-FMA has not been extensively studied, and it needs a history of widespread human use. Harm reduction practices are strongly recommended for those considering its use.

4. Are there any known health risks associated with 2-FMA?

Due to limited research, the long-term health effects and exact toxic dosage of 2-FMA remain unknown. Some users have reported adverse effects at higher doses, but comprehensive data is lacking.

5. Is 2-FMA addictive?

Like other stimulants, 2-FMA can be moderately addictive, with a potential for psychological dependence in some users. Cravings and withdrawal symptoms may occur with chronic use.

6. What is the typical dosage of 2-FMA?

Dosages vary, but users often start with low to moderate amounts, typically 10 to 40 milligrams. It’s essential to exercise caution and avoid excessive doses.

7. How long do the effects of 2-FMA last?

The duration of 2-FMA effects is comparable to amphetamines, generally lasting around 4 to 6 hours. Individual responses may vary.

8. Is 2-FMA legal?

The legal status of 2-FMA varies by country. In some places, it is unregulated and exists in a legal grey area, while in others, it may be classified as a controlled substance. Always check local laws and regulations before acquiring or using 2-FMA.

9. Are there any dangerous drug interactions with 2-FMA?

There are potential interactions, especially when combined with alcohol, GHB/GBL, opioids, cocaine, cannabis, and more. These combinations can pose health risks and should be avoided.

10. Where can I find 2-FMA for sale?

The sale and availability of 2-FMA can vary widely depending on your location and local laws. It is essential to exercise caution and ensure you abide by your country’s regulations if you choose to obtain it.

Remember that using any substance carries inherent risks, and it’s crucial to prioritize your safety and well-being. Always consult with a healthcare professional or seek reliable sources for information when considering using 2-FMA or any other research chemical.


  1. Camilleri, A., Johnston, M. R., Brennan, M., Davis, S., Caldicott, D. G. E. (April 2010). “Analysis of Four Capsules Containing Controlled Substance Analogues: 4-Methylmethcathinone, 2-Fluoromethamphetamine, α-Phthalimidopropiophenone, and N-Ethylcathinone.” Published in Forensic Science International, Volume 197 (1–3), Pages 59–66. DOI: 10.1016/j.forsciint.2009.12.048. ISSN: 0379-0738.
  2. Emerging Trends – National Institute on Drug Abuse
  3. Shoptaw, S. J., Kao, U., Ling, W. (21 January 2009). “Amphetamine Psychosis Treatment” in Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.CD003026.pub3. ISSN: 1465-1858.
  4. Hofmann, F. G. (1983). “Biomedical Aspects of Drug and Alcohol Abuse: A Handbook” (2nd ed.). Published by Oxford University Press. ISBN: 9780195030563.
  5. Greenwald, M. K., Lundahl, L. H., Steinmiller, C. L. (December 2010). “Sustained Release d-Amphetamine Reduces Cocaine but not ‘Speedball’-Seeking in Buprenorphine-Maintained Volunteers: Dual-Agonist Pharmacotherapy for Cocaine/Heroin Polydrug Abusers.” Published in Neuropsychopharmacology, Volume 35 (13), Pages 2624–2637. DOI: 10.1038/npp.2010.175. ISSN: 0893-133X.
  6. Siciliano, C. A., Saha, K., Calipari, E. S., Fordahl, S. C., Chen, R., Khoshbouei, H., Jones, S. R. (10 January 2018). “Amphetamine Reverses Escalated Cocaine Intake via Restoration of Dopamine Transporter Conformation.” Published in The Journal of Neuroscience, Volume 38 (2), Pages 484–497. DOI: 10.1523/JNEUROSCI.2604-17.2017. ISSN: 0270-6474.
  7. Krystal, J. H., Perry, E. B., Gueorguieva, R., Belger, A., Madonick, S. H., Abi-Dargham, A., Cooper, T. B., MacDougall, L., Abi-Saab, W., D’Souza, D. C. (1 September 2005). “Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine: Implications for Glutamatergic and Dopaminergic Model Psychoses and Cognitive Function.” Published in Archives of General Psychiatry, Volume 62 (9), Page 985. DOI: 10.1001/archpsyc.62.9.985. ISSN: 0003-990X.
  8. Branch, L. S. (2022). “Consolidated Federal Laws of Canada: Controlled Drugs and Substances Act.”
  9. “关于印发《非药用类麻醉药品和精神药品列管办法》的通知” (in Chinese). Issued by China Food and Drug Administration on 27 September 2015. Retrieved on 1 October 2015.
  10. “Anlage I BtMG” (in German). Published by Bundesministerium der Justiz und für Verbraucherschutz. Retrieved on December 19, 2019.
  11. “Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften” (in German). Published by Bundesanzeiger Verlag. Retrieved on December 19, 2019.
  12. “§ 29 BtMG” (in German). Published by Bundesministerium der Justiz und für Verbraucherschutz. Retrieved on December 19, 2019.
  13. Misuse of Drugs Act 1975 No 116 (as at 01 July 2022), Public Act – New Zealand Legislation.
  14. “Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien” (in German). Published by Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved on January 1, 2020.
  15. Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü
  16. “Про внесення змін до переліку наркотичних засобів, психотропних речовин і прекурсорів”

Leave a Comment

Your email address will not be published. Required fields are marked *